NOT-HG-22-030 - Notice of Intent to Publish a Funding Opportunity Announcement for Diversity Centers for Genome Research (U54 Clinical Trials Optional)
National Human Genome Research Institute (NHGRI)
The National Human Genome Research Institute, with other NIH Institutes and Centers (ICs)-- the National Institute of Mental Health and the National Institute on Minority Health and Disparities, intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to establish Diversity Centers for Genomic Research (DCGR) at Minority Serving Institutions (MSIs) (as defined below). Each DCGR award will support the development and planning for a multi-investigator, interdisciplinary team to develop administrative, genomic workforce development and community engagement cores and 2-3 interrelated, innovative genomic research projects that address one or more critical issues in genomics including: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; genomic data science and computational genomics, ethical, legal, and social implications of genomic research (ELSI); and/or genomics and health equity. The outcome of the development and feasibility studies will be fully developed plans to carry out all activities of a full-scale Diversity Center for Genome Research. Along with its scientific goals, the DCGR will expand the pool of genomic scientists, clinician scientists, and researchers from diverse backgrounds, including those from groups that are underrepresented in biomedical research, who can perform innovative genomics research by providing didactic, practicum and research activities and experiences that are aligned with the research projects.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
The FOA is expected to be published in late summer 2022 with an expected application due date in Winter 2022.
This FOA will utilize the UG3/UH3 activity code. Details of the planned FOA are provided below.
Minority Serving Institutions (MSIs) have played an important role in supporting scientific research and graduating and training individuals from underrepresented backgrounds in science, technology, engineering and math (STEM) disciplines.
This initiative focuses on a two-phase approach to enhancing diversity (see NIH Interest in Diversity: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-031.html) in genomics research:
In Phase I, Centers will enhance genomic research capacity, develop plans, and test feasibility of carrying out innovative, state-of-the-art genomic research studies; fostering genomic research career development and enhancement for trainees and investigators at all career levels; enhancing the genomic infrastructure, computational, analytical and ELSI research capability within eligible Minority Serving Institutions (MSIs) (as defined below); establishing sustainable partnerships and disseminating resources and findings.
In Phase II, Centers will support an Administrative Core, Genomic Workforce Development Core, Community Engagement Core, and two to three interrelated, innovative genomic research projects that address one or more critical issues in the following: genomic technology and methods development; genome structure; genome function; genomics of disease; use and impact of genomic information in clinical care; ethical, legal, and social implications of genomic research; genomics and health equity; and/or computational genomics.
The following list provides some examples of different types of topics that could be the focus of a Diversity Center for Genome Research. The examples listed are not exhaustive and are meant only to provide guidance.
National Human Genome Research Institute (NHGRI)
Genetic/environmental, including social determinants of health, contributors to disease. A Center application may involve collection of new samples and/or the use of existing samples from one or more populations of interest to study the genetic epidemiology of a diseases or disorders that present a significant public health burden. The individuals from whom samples are collected or re-used should be well-phenotyped to ensure that the disease being studied has been properly diagnosed.
Function Genomics. Functional genomics includes an assessment of how the genome functions, how genomic variation affects genome function to influence phenotypes, and how processes in the body are influenced by genomic variation.
An assessment of inherited diseases. An analysis of individuals affected by monogenic diseases or complex genetic disorders to identify causative mutations, modifier genes, and environmental risk factors during early development.
Pharmacogenomics. Pharmacogenomics research seeks to identify genetic factors that are responsible for individual differences in drug efficacy and susceptibility to adverse drug reactions as well as the role these individual differences may play in the development of antimicrobial resistance.
Ethical, Legal, and Social Implications (ELSI). ELSI research seeks to identify, analyze, and address the ELSI of genomic technological and scientific advances for individuals, families, communities, and society.
Genomic Medicine. Genomic medicine is an emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g. for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use.
Bioinformatics. Advances in tools and techniques for data generation are rapidly increasing the amount of data available to researchers, particularly in genomics requires researchers to rely more heavily on computational and data science tools for the storage, management, analysis, and visualization of data. Projects could include research and development of transformative approaches and tools that maximize the integration of data (e.g., genomics data, environmental measures, phenotypes, and biomarkers) and data science into biomedical research.
Genomic Technology Development. Research in genomic technology development seeks to advance methods, technologies, and instruments needed to generate increasingly complex genomic data, including new and improved methods for sequencing nucleic acids, detecting genomic variation, and mapping epigenomic and epitranscriptomic features.
Genome Structure and Function. Research in genome structure and function utilizes high-throughput genomic methods to understand how the genome is organized, to detect structurally complex genome variation and 3D genome organization, to assess how the genome functions, and to assess how genomic variation affects genome function to influence phenotypes, including those related to human health and disease.
National Institute of Mental Health (NIMH)
NIMH is interested in research programs examining the contribution of genetic and genomic factors to risk and resilience in psychiatric disorders in ancestrally diverse populations as described in our strategic objectives:
Specific interests include but not limited to the following:
National Institute on Minority Health and Health Disparities (NIMHD)
NIMHD encourages projects that use approaches encompassing multiple domains of influence (e.g., biological, behavioral, sociocultural, environmental, physical environment, health system) and multiple levels of influence (e.g., individual, interpersonal, family, peer group, community, societal) to understand and address minority health and health disparities (see the NIMHD Research Framework,https://www.nimhd.nih.gov/about/overview/research-framework.html, for more information).
Specific interest include but not limited to the following:
For the purposes of the FOA, to be eligible for the initiative, the applicant institution must be a domestic institution located in the United States and its territories which:
NHGRI and partner components intend to commit up to an estimated total of $1,500,000 in FY23.
NHGRI and partner components intend to fund four awards.
$200,000 Direct Cost per year for the UG3 Phase and $1,400,000 Direct Cost per year for the UH3 phase.
93.172, 93.307, 93.242
Applications are not being solicited at this time.
Please direct all inquiries to:
Ebony Madden, Ph.D.
National Human Genome Research Institute